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Results ConclusionsIntroduction
Alzheimer’s disease is a neurodegenerative disease caused by the 
incorrect cleaving of the transmembrane Amyloid Precursor Protein into the 
neurotoxic Aβ40 and Aβ42 fragments
2. These fragments are soluble oligomers 
with a random coil conformation that can impair synapses or 
neurotransmission; they may also aggregate into parallel and antiparallel 
beta sheets to form amyloid plaques, which can block or distort signaling 
between neuronal pathways7.
Aβ fibrils self-assemble into parallel and antiparallel beta sheets on 
hydrophobic graphite, but not on hydrophilic mica5,6. Aβ fibrils also assemble 
on graphene, which irreversibly captures fibrils3, suggesting graphene might 
have a role in the study of Alzheimer’s amyloid plaque.
These studies characterize binding between amyloid beta peptide 
fibrils and graphene using Raman spectroscopy, scanning electron 
microscopy (SEM), and circular dichroism (CD). The goal is to provide 
evidence that graphene can attract free floating Aβ fibrils and Aβ plaque. 
Both studies currently use diphenylalanine peptide, a self-assembling model 
peptide for Aβ fibrils.
Experiment 1 explored if diphenylalanine easily bound to graphene 
dispersed in 7xTE, which is ideal for keeping graphene powder in an even 
suspension within a solution. Graphene did bind to diphenylalanine, with a 
higher binding rate in a 2:1 gr:diphe ratio, but otherwise the binding efficacy 
was seemingly random and unreliable. Furthermore, the reference article4
found ideal binding occurred in the 3.7-5.4 pH range. This study’s samples 
had a 7.3 pH to mimic cerebrospinal fluid.
Experiment 2 successfully created the self-assembling 
diphenylalanine nanotubes in ddH20 from the reference article
1. The 
nanotubes were confirmed in both SEM and CD analysis. The control did not 
self-assemble nor did the diphenylalanine/HFIP stock solution, which may 
further explain why there was less than ideal binding in Experiment 1 and no 
binding between the stock diphenylalanine/HFIP solution in Experiment 2. 
These experiments have demonstrated that there are binding 
capabilities between graphene and diphenylalanine, even in less than ideal 
situations. Diphenylalanine was chosen because its two phenylalanines 
mimic those in amyloid beta peptides. There results are sufficient to continue 
Experiment 1
Signs of binding include fanned out or twisted cylinders with graphene “scales” or “ridges” on 
them. All samples were prevalently graphene with no observable effect from diphenylalanine.
Graphene powder at x1000 under the SEM. Graphene in 7x TE (1 mg/mL) at x1000 under the SEM.
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Experiment 1
-For the SEM, a stock solution of diphenylalanine dissolved in 1,1,1,3,3,3-
hexafluouro-2-propanol (HFIP) (100 mg/mL) was added to graphene dispersed 
in 7x TE (1 mg/mL). All samples were dried on aluminum stubs  coated with 
gold. A total of fourteen samples were analyzed. 
-Samples 1 and 2 were the stock graphene and diphenylalanine solutions
-Samples 3-14 were three sets of four samples each. The 1st of a set was not 
shaken; the 2nd was hand shaken; the 3rd was vortex shaken; the 4th was 
sonicated. -Samples 2-6 had a 1:1 ratio of graphene and diphenylalanine; 
samples 7-10 had a 2:1 ratio; samples 11-14 had a 1:2 ratio. 
Experiment 2
-For the CD spectra, a stock solution of diphenylalanine was dissolved in HFIP 
(100mg/mL)  was diluted into ddH20 to a 2 mg/mL concentration, and then 
immediately diluted again into ddH20 to a 0.04 mg/mL concentration. A control 
solution of dialanine was made under the same conditions. Controls of ddH20 
and HFIP were analyzed.
-For the SEM, a stock solution of diphenylalanine was dissolved in HFIP 
(100mg/mL), then diluted into ddH20 to a 2 mg/mL concentration. A control 
solution of dialanine was made under the same conditions. A solution of 
graphene in 7x TE (1 mg/mL) was added to the stock solution of diphenylalanine 
in a 1:1 and 2:1 (gr:diphe) ratio.
Note: All Experiment 2 solutions were vortexed before and after every 
combination.
experiments using amyloid beta peptide instead of diphenylalanine with a few 
small changes in methodology. Sample 10: 2:1 gr:diphe, sonicated at x300. The fanned out        Sample 8: 2:1 gr:diphe, hand shaken at x30. There are
cylinders are circled in red. The twisted cylinders are twisted cylinders all over the surface, some circled in blue.
circled in blue. Some droplets of gold left by SEM
preparation are circled in yellow. The rest is graphene.
Experiment 2
The diphenylalanine samples self-assembled into nanotubes, while the dialanine control did 
not. The diphenylalanine-graphene solutions did not show signs of binding.
Diphenylalanine and HFIP diluted in ddH2O (2 mg/mL).                 Dialanine and HFIP diluted in ddH2O (2 mg/mL).
CD spectra of diphenylalanine and HFIP diluted in ddH2O            CD spectra of dialanine and HFIP diluted in ddH2O 
(0.04 mg/mL). The dual peaks at 200 and 220 nm are (0.04 mg/mL). The downward slope as the spectra
indicative of self-assembled binding. Approaches 200 nm implies no binding in this sample.
The next step is to recreate an aqueous graphene dispersion using a 
modified Hummers method4 and determine if it is a better medium for 
diphenylalanine binding than 7x TE, since 7x TE is a possible deterrent of 
binding, and ddH20 is a possible enabler. Once the more productive dispersion 
solution is determined, we will experiment the conditions of binding between 
graphene and amyloid beta peptide, whether in random coil or beta sheet 
conformation. The pH will remain comparable to that of cerebrospinal fluid.
Afterwards, experimentation of amyloid beta peptide to graphene will be 
done in artificial cerebrospinal fluid to determine how the extracellular fluid in the 
brain may change the reactions between Aβ and graphene. It is possible 
hydrophilic mica may be present to imitate hydrophilic cell membranes of 
neurons in the brain.
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